The Janssen COVID-19 vaccine is now limited to certain individuals ages 18 and up after the U.S. Food and Drug Administration downgraded its emergency use authorization.
Merck’s cardiopulmonary pipeline is poised to deliver eight potential approvals over the next eight years, bolstering the company’s pipeline and revenue.
AstraZeneca’s Covid-19 vaccine carries a small extra risk of rare blood clots with low platelets after the first dose and no extra risk after the second, a study led and funded by the drugmaker showed on July 28, after worries over side effects.
Anthos Therapeutics is developing next-generation anticoagulants that do not have the bleeding risks that current blood thinners have.
Biogen, headquartered in Cambridge, Massachusetts, signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.
U.S. FDA staff flagged concerns about potentially fatal blood clots from higher doses of a rheumatoid arthritis drug developed by Eli Lilly and Co. and Incyte Corp.
Roche Holding AG’s emicizumab drug for treating hemophilia A showed it worked in a phase III study, the Swiss drugmaker said.
Four patients have suffered serious adverse events in a clinical trial of an experimental hemophilia medicine from Roche, the Swiss group said, clouding prospects for its potential blockbuster product.
GlaxoSmithKline is to sell its portfolio of anesthetic drugs to South Africa’s Aspen Pharmacare for up to 280 million pounds ($372 million).
Artificial Blood Vessels Become Resistant To Thrombosis Scientists from ITMO University developed artificial blood vessels that are not susceptible to blood clot formation. The achievement was made possible by a […]
